JP2009528389A - Ａ２ａアデノシン受容体拮抗剤 - Google Patents

Ａ２ａアデノシン受容体拮抗剤 Download PDF

Info

Publication number
JP2009528389A
JP2009528389A JP2008557512A JP2008557512A JP2009528389A JP 2009528389 A JP2009528389 A JP 2009528389A JP 2008557512 A JP2008557512 A JP 2008557512A JP 2008557512 A JP2008557512 A JP 2008557512A JP 2009528389 A JP2009528389 A JP 2009528389A
Authority
JP
Japan
Prior art keywords
dihydrothiopheno
pyrimidine
methyl
dione
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008557512A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009528389A5 (https=
Inventor
エルファティー エルジン，
ラオ カーラ，
ジェフ サブロッキ，
シャオフェン リー，
タオ ペリー，
徹也 小林
エリック パークヒル，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Palo Alto Inc
Original Assignee
CV Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CV Therapeutics Inc filed Critical CV Therapeutics Inc
Publication of JP2009528389A publication Critical patent/JP2009528389A/ja
Publication of JP2009528389A5 publication Critical patent/JP2009528389A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2008557512A 2006-03-02 2007-03-02 Ａ２ａアデノシン受容体拮抗剤 Pending JP2009528389A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77882106P 2006-03-02 2006-03-02
US81574506P 2006-06-21 2006-06-21
PCT/US2007/063143 WO2007103776A2 (en) 2006-03-02 2007-03-02 A2a adenosine receptor antagonists

Publications (2)

Publication Number Publication Date
JP2009528389A true JP2009528389A (ja) 2009-08-06
JP2009528389A5 JP2009528389A5 (https=) 2011-04-07

Family

ID=38475714

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008557512A Pending JP2009528389A (ja) 2006-03-02 2007-03-02 Ａ２ａアデノシン受容体拮抗剤

Country Status (5)

Country Link
US (1) US20070208040A1 (https=)
EP (1) EP1989210A2 (https=)
JP (1) JP2009528389A (https=)
CA (1) CA2644996A1 (https=)
WO (1) WO2007103776A2 (https=)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014533281A (ja) * 2011-11-11 2014-12-11 ニンバス アポロ， インコーポレイテッド Ａｃｃ阻害剤およびその使用
JP2016532721A (ja) * 2013-10-07 2016-10-20 バイエル ファーマ アクチエンゲゼルシャフト 環状チエノウラシルカルボキサミドおよびその使用
JP2017524016A (ja) * 2014-08-11 2017-08-24 ハイドラ バイオサイエンシズ インコーポレイテッドＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． ＴＲＰＣ５調節因子としての、精神神経障害の処置のためのチエノおよびフロ［２，３−ｄ］ピリミジン−２，４［１Ｈ，３Ｈ］−ジオン誘導体
JP2018509443A (ja) * 2015-03-26 2018-04-05 バイエル ファーマ アクチエンゲゼルシャフト アデノシン−Ａ２ｂ受容体の拮抗薬としての複素環メチル−チエノウラシル
US10179793B2 (en) 2015-10-26 2019-01-15 Gilead Apollo, Llc ACC inhibitors and uses thereof
US10183951B2 (en) 2016-03-02 2019-01-22 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof
JP2020527160A (ja) * 2017-07-26 2020-09-03 南京聖和薬業股▲ふん▼有限公司Ｎａｎｊｉｎｇ Ｓａｎｈｏｍｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． Ａｃｃ阻害剤としての化合物及びその応用
US10800791B2 (en) 2015-11-25 2020-10-13 Gilead Apollo, Llc Triazole ACC inhibitors and uses thereof
US10941157B2 (en) 2015-11-25 2021-03-09 Gilead Apollo, Llc Pesticidal compositions and uses thereof
US10941158B2 (en) 2015-11-25 2021-03-09 Gilead Apollo, Llc Pyrazole ACC inhibitors and uses thereof
US11098055B2 (en) 2015-11-25 2021-08-24 Gilead Apollo, Llc Ester ACC inhibitors and uses thereof
US11833150B2 (en) 2017-03-28 2023-12-05 Gilead Sciences, Inc. Methods of treating liver disease

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008000743A2 (en) * 2006-06-27 2008-01-03 Biovitrum Ab (Publ) Novel 2',3'-methylidene acetyl adenosine prodrugs for use as prodrugs for adenosine receptor agonists
EP2121705A2 (en) * 2006-12-01 2009-11-25 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
GB0718432D0 (en) * 2007-09-21 2007-10-31 Vernalis R&D Ltd New chemical compounds
GB0718434D0 (en) * 2007-09-21 2007-10-31 Vernalis R&D Ltd New chemical compounds
TWI473614B (zh) 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
US20100093723A1 (en) * 2008-10-13 2010-04-15 Barbay J Kent HETEROCYCLYL AND CYCLOALKYL SUBSTITUTED THIENO[2,3 d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
US20100093721A1 (en) * 2008-10-13 2010-04-15 Barbay J Kent PHENYL AND HETEROARYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
US20100093722A1 (en) * 2008-10-13 2010-04-15 Barbay J Kent HETEROARYL AND PHENYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
WO2011061754A1 (en) * 2009-11-18 2011-05-26 Council Of Scientific & Industrial Research A novel 3-substituted 7-imino-2-thioxo-3, 7-dihydro-2h-thiazolo [4,5-di pyrimidin-6-yl - and process for preparation thereof
EA201591959A1 (ru) * 2013-05-10 2016-03-31 Нимбус Аполло, Инк. Ингибиторы акк и их применение
CA2911818A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
AU2014262547A1 (en) 2013-05-10 2015-11-26 Gilead Apollo, Llc ACC inhibitors and uses thereof
MX2015015422A (es) 2013-05-10 2016-06-21 Nimbus Apollo Inc Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
US20150301030A1 (en) 2014-04-22 2015-10-22 Q-State Biosciences, Inc. Models for parkinson's disease studies
US12006328B2 (en) 2014-11-18 2024-06-11 Emory University Thieno[2,3-d]pyrimidin-4-one derivatives as NMDAR modulators and uses related thereto
WO2018041771A1 (de) 2016-09-02 2018-03-08 Bayer Pharma Aktiengesellschaft (1-methylcyclopropyl)methyl-substituierte thienouracile und ihre verwendung
WO2018054846A1 (de) 2016-09-23 2018-03-29 Bayer Aktiengesellschaft N3-cyclisch substituierte thienouracile und ihre verwendung
CN108341830B (zh) 2017-01-22 2021-03-02 广东东阳光药业有限公司 噻吩并嘧啶衍生物及其在药物中的应用
AU2018277241B2 (en) * 2017-05-31 2021-03-04 Novartis Ag Crystalline forms of 5-bromo-2,6-di(1H-pyrazol-1- yl)pyrimidin-4-amine and new salts
WO2020139803A1 (en) * 2018-12-24 2020-07-02 Dcb-Usa Llc Benzothiadiazine derivatives and compositions comprising the same for treating disorders mediated by adenosine
EP3995498A4 (en) 2019-07-02 2023-03-01 Sunshine Lake Pharma Co., Ltd. THIENOPYRIMIDI DERIVATIVES WITH STEREO CONFIGURATION AND THEIR USE IN MEDICINE
CN119173276A (zh) 2022-04-13 2024-12-20 吉利德科学公司 用于治疗表达Trop-2的癌症的组合疗法
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01121291A (ja) * 1987-10-06 1989-05-12 Ferrosan:As ヘテロ環式化合物ならびにその製造方法および使用方法
JPH08269060A (ja) * 1995-02-24 1996-10-15 Ono Pharmaceut Co Ltd ヘテロ環化合物、その製造方法およびそれを含有する医薬品
JP2002500666A (ja) * 1997-05-28 2002-01-08 アストラゼネカ・アクチエボラーグ 新規な化合物
JP2002523511A (ja) * 1998-08-28 2002-07-30 アストラゼネカ・アクチエボラーグ 新規化合物
JP2003513976A (ja) * 1999-11-12 2003-04-15 バイオジェン インコーポレイテッド アデノシンレセプターアンタゴニストおよびこれを作製し使用する方法
JP2003523380A (ja) * 2000-02-25 2003-08-05 エフ．ホフマン−ラ ロシュ アーゲー アデノシン受容体モジュレーター
JP2004518732A (ja) * 2001-02-14 2004-06-24 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテイナーゼ阻害剤としてのチエノ’２，３−ｄピリミジンジオン誘導体
JP2004524293A (ja) * 2001-01-10 2004-08-12 バーナリス リサーチ リミテッド チエノ（３，２−ｄ）ピリミジンおよびフラノ（３，２−ｄ）ピリミジン、ならびにそれらのプリン作動性レセプターアンタゴニストとしての使用
WO2004106337A1 (en) * 2003-05-06 2004-12-09 Cv Therapeutics, Inc. Xanthine derivatives as a2b adenosine receptor antagonists
WO2005042534A2 (en) * 2003-10-31 2005-05-12 Cv Therapeutics, Inc. A2b adenosine receptor antagonists
JP2006502113A (ja) * 2002-07-17 2006-01-19 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー マトリックス・メタロプロテイナーゼ−１３アロステリック阻害剤と、セレコキシブ又はバルデコキシブでないシクロオキシゲナーゼ−２選択的阻害剤との複合体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) * 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) * 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
EP0335979A4 (en) * 1987-09-16 1992-02-26 Taiho Pharmaceutical Company, Limited Thienopyrimidine derivatives
US6878715B1 (en) * 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
EP1465634B1 (en) * 2001-12-12 2014-10-22 The Government of the United States of America, as represented by the Secretary Department of Health and Human Services Methods for using adenosine receptor inhibitors to enhance immune response and inflammation
ES2208063B1 (es) * 2002-04-01 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de la 4-(pirrolopirimidin-6-il)bencenosulfonamida.
MXPA05000729A (es) * 2002-07-17 2005-04-08 Warner Lambert Co Combinacion de un inhibidor alosterico de metaloproteinasa-13 de matriz con celecoxib o valdecoxib.
PL1628662T3 (pl) * 2003-05-21 2007-07-31 Hoffmann La Roche Pochodne benzotiazolu i ich zastosowanie w leczeniu chorób związanych z receptorem adenozynowym A2A
US7523193B2 (en) * 2004-05-18 2009-04-21 International Business Machines Corporation Method and apparatus for DNS pre-fetching for multiple clients
EP2121705A2 (en) * 2006-12-01 2009-11-25 Cv Therapeutics, Inc. A2a adenosine receptor antagonists

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01121291A (ja) * 1987-10-06 1989-05-12 Ferrosan:As ヘテロ環式化合物ならびにその製造方法および使用方法
JPH08269060A (ja) * 1995-02-24 1996-10-15 Ono Pharmaceut Co Ltd ヘテロ環化合物、その製造方法およびそれを含有する医薬品
JP2002500666A (ja) * 1997-05-28 2002-01-08 アストラゼネカ・アクチエボラーグ 新規な化合物
JP2002523511A (ja) * 1998-08-28 2002-07-30 アストラゼネカ・アクチエボラーグ 新規化合物
JP2003513976A (ja) * 1999-11-12 2003-04-15 バイオジェン インコーポレイテッド アデノシンレセプターアンタゴニストおよびこれを作製し使用する方法
JP2003523380A (ja) * 2000-02-25 2003-08-05 エフ．ホフマン−ラ ロシュ アーゲー アデノシン受容体モジュレーター
JP2004524293A (ja) * 2001-01-10 2004-08-12 バーナリス リサーチ リミテッド チエノ（３，２−ｄ）ピリミジンおよびフラノ（３，２−ｄ）ピリミジン、ならびにそれらのプリン作動性レセプターアンタゴニストとしての使用
JP2004518732A (ja) * 2001-02-14 2004-06-24 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテイナーゼ阻害剤としてのチエノ’２，３−ｄピリミジンジオン誘導体
JP2006502113A (ja) * 2002-07-17 2006-01-19 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー マトリックス・メタロプロテイナーゼ−１３アロステリック阻害剤と、セレコキシブ又はバルデコキシブでないシクロオキシゲナーゼ−２選択的阻害剤との複合体
WO2004106337A1 (en) * 2003-05-06 2004-12-09 Cv Therapeutics, Inc. Xanthine derivatives as a2b adenosine receptor antagonists
WO2005042534A2 (en) * 2003-10-31 2005-05-12 Cv Therapeutics, Inc. A2b adenosine receptor antagonists

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
JPN5009001363; ＡＲＹＡ　Ｖ　Ｐ: ＩＮＤＩＡＮ　ＪＯＵＲＮＡＬ　ＯＦ　ＣＨＥＭＩＳＴＲＹ Ｖ９, 197111, Ｐ１２０９-１２１２ *
JPN5009001365; ＲＯＭＥＯ　Ｇ: ＡＲＺＥＮＥＩＭＩＴＴＥＬ　ＦＯＲＳＣＨＵＮＧ．ＤＲＵＧ　ＲＥＳＥＡＲＣＨ Ｖ４８　Ｎ１, 1998, Ｐ１６７-１７２, ＥＣＶ　ＥＤＩＴＩＯ　ＣＡＮＴＯＲ　ＶＥＲＬＡＧ *
JPN5009001366; ＧＵＥＴＳＣＨＯＷ　Ｍ: ＪＯＵＲＮＡＬ　ＯＦ　ＭＥＤＩＣＩＮＡＬ　ＣＨＥＭＩＳＴＲＹ Ｖ４１　Ｎ１０, 1998, Ｐ１７２９-１７４０, ＡＭＥＲＩＣＡＮ　ＣＨＥＭＩＣＡＬ　ＳＯＳＩＥＴＹ *
JPN5009001367; ＫＯＳＡＫＵ　ＨＩＲＯＴＡ: ＪＯＵＲＮＡＬ　ＯＦ　ＨＥＴＥＲＯＣＹＣＬＩＣ　ＣＨＥＭＩＳＴＲＹ Ｖ２７, 1990, Ｐ７１７-７２１ *
JPN5009001368; ＨＯＳＮＩ，ＨＡＮＡＡ　Ｍ．: ＥＧＹＰＴＩＡＮ　ＪＯＵＲＮＡＬ　ＯＦ　ＣＨＥＭＩＳＴＲＹ Ｖ４２　Ｎ５, 1999, Ｐ４６９-４８０ *
JPN6012042873; Ｃｈｅｍｉｃａｌ　＆　Ｐｈａｒｍａｃｅｕｔｉｃａｌ　Ｂｕｌｌｅｔｉｎ Ｖｏｌ．３０，　Ｎｏ．１, 1982, ｐｐ．２８-３４ *
JPN6012042874; ＣＡ　Ａｃｃｅｓｓｉｏｎ　ｎｏ．１９７７：６０１４５２　Ｒｅｔｒｉｅｖｅｄ　ｆｒｏｍ　ＳＴＮ　ｉｎｔｅｒｎａｔｉｏｎａｌ［ｏｎｌｉｎｅ］；　ｒｅｔｒｉｅｖｅｄ　ｏｎ　１０　Ａｕｇｕｓｔ　２０１２，　Ｒ *
JPN6012042875; Ｅｕｒｏｐｅａｎ　Ｊｏｕｒｎａｌ　ｏｆ　Ｍｅｄｉｃｉｎａｌ　Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．３９, 2004, ｐｐ．８７９-８８７ *
JPN6012042876; Ｊｏｕｒｎａｌ　ｏｆ　Ｍｅｄｉｃｉｎａｌ　Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．４０, 1997, ｐｐ．４３９６-４４０５ *
JPN6012042877; Ｅｕｒｏｐｅａｎ　Ｊｏｕｒｎａｌ　ｏｆ　Ｍｅｄｉｃｉｎａｌ　Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．３２, 1997, ｐｐ．７０９-７１９ *
JPN6012042878; Ｄｒｕｇ　Ｄｅｓｉｇｎ　ａｎｄ　Ｄｉｓｃｏｖｅｒｙ Ｖｏｌ．１２, 1994, ｐｐ．１６９-１７７ *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019147847A (ja) * 2011-11-11 2019-09-05 ギリアド アポロ， エルエルシー Ａｃｃ阻害剤およびその使用
US9453026B2 (en) 2011-11-11 2016-09-27 Gilead Apollo, Inc. ACC inhibitors and uses thereof
JP2017114910A (ja) * 2011-11-11 2017-06-29 ギリアド アポロ， エルエルシー Ａｃｃ阻害剤およびその使用
JP2018052989A (ja) * 2011-11-11 2018-04-05 ギリアド アポロ， エルエルシー Ａｃｃ阻害剤およびその使用
JP2014533281A (ja) * 2011-11-11 2014-12-11 ニンバス アポロ， インコーポレイテッド Ａｃｃ阻害剤およびその使用
US9944655B2 (en) 2011-11-11 2018-04-17 Gilead Apollo, Llc ACC inhibitors and uses thereof
US10472374B2 (en) 2011-11-11 2019-11-12 Gilead Apollo, Llc ACC inhibitors and uses thereof
JP2016532721A (ja) * 2013-10-07 2016-10-20 バイエル ファーマ アクチエンゲゼルシャフト 環状チエノウラシルカルボキサミドおよびその使用
JP2017524016A (ja) * 2014-08-11 2017-08-24 ハイドラ バイオサイエンシズ インコーポレイテッドＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． ＴＲＰＣ５調節因子としての、精神神経障害の処置のためのチエノおよびフロ［２，３−ｄ］ピリミジン−２，４［１Ｈ，３Ｈ］−ジオン誘導体
JP2018509443A (ja) * 2015-03-26 2018-04-05 バイエル ファーマ アクチエンゲゼルシャフト アデノシン−Ａ２ｂ受容体の拮抗薬としての複素環メチル−チエノウラシル
US10179793B2 (en) 2015-10-26 2019-01-15 Gilead Apollo, Llc ACC inhibitors and uses thereof
US10800791B2 (en) 2015-11-25 2020-10-13 Gilead Apollo, Llc Triazole ACC inhibitors and uses thereof
US10941157B2 (en) 2015-11-25 2021-03-09 Gilead Apollo, Llc Pesticidal compositions and uses thereof
US10941158B2 (en) 2015-11-25 2021-03-09 Gilead Apollo, Llc Pyrazole ACC inhibitors and uses thereof
US11098055B2 (en) 2015-11-25 2021-08-24 Gilead Apollo, Llc Ester ACC inhibitors and uses thereof
US10183951B2 (en) 2016-03-02 2019-01-22 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof
US10487090B2 (en) 2016-03-02 2019-11-26 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof
US11104687B2 (en) 2016-03-02 2021-08-31 Gilead Apollo, Llc Solid forms for a thienopyrimidinedione ACC inhibitor and methods for production thereof
US11912718B2 (en) 2016-03-02 2024-02-27 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof
US11833150B2 (en) 2017-03-28 2023-12-05 Gilead Sciences, Inc. Methods of treating liver disease
JP2020527160A (ja) * 2017-07-26 2020-09-03 南京聖和薬業股▲ふん▼有限公司Ｎａｎｊｉｎｇ Ｓａｎｈｏｍｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． Ａｃｃ阻害剤としての化合物及びその応用

Also Published As

Publication number Publication date
EP1989210A2 (en) 2008-11-12
WO2007103776A3 (en) 2007-12-13
WO2007103776A2 (en) 2007-09-13
CA2644996A1 (en) 2007-09-13
US20070208040A1 (en) 2007-09-06

Similar Documents

Publication Publication Date Title
JP2009528389A (ja) Ａ２ａアデノシン受容体拮抗剤
KR102824407B1 (ko) Rip1 억제 화합물 및 그를 제조 및 사용하는 방법
JP4450365B2 (ja) 多環式グアニンホスホジエステラーゼｖ阻害剤
CA3009193C (en) 4-amino-2-(1h-pyrazolo[3,4-b]pyridin-3-yl)-6-oxo-6,7-dihydro-5h-pyrrolo[2,3-d]pyrimidine derivatives and the respective (1h-indazol-3-yl) derivatives as cgmp modulators for treating cardiovascular diseases
JP6291103B2 (ja) 抗ウイルス処置のための化合物および方法
AU2013312931B2 (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
KR102824962B1 (ko) 헤테로시클릭 rip1 억제 화합물
CN100415748C (zh) A2b腺苷受体拮抗剂
US7776868B2 (en) Substituted bicyclic and tricyclic thieno[2,3-d]pyrimidines as A2A adenosine receptor antagonists
JP2004517861A (ja) プリン作動性レセプターアンタゴニストとしてのピラゾロ［３，４−ｄ］ピリミジン誘導体およびそれらの使用
CN103096718A (zh) 可溶性鸟苷酸环化酶活化剂
TW201313718A (zh) 用於治療肺動脈高血壓之雙環雜環衍生物
JP2008534486A (ja) Ｖｒ１拮抗剤としての２，３−置換縮合ピリミジン−４（３ｈ）−オン
JP2006502984A (ja) ヘテロ環により置換されているイミダゾトリアジン類
JP2020532545A (ja) スピロ環化合物並びにその作製及び使用方法
ES2363672T3 (es) TRIAZOLO[1,5-a]QUINOLINAS COMO LIGANDOS DEL RECEPTOR A3 DE ADENOSINA.
KR20200100696A (ko) sGC 자극제
WO2015091531A1 (en) Imidazolopyrimidin-2-yl derivatives as jak inhibitors
US20130345243A1 (en) 1h-pyrollo[3,2-d]pyrimidinedione derivatives
CA3011442A1 (en) Compounds antagonizing a3 adenosine receptor, method for preparing them, and medical-use thereof
CN114656472B (zh) 吡唑并嘧啶类化合物、异构体或盐及其制备方法和用途
CN114891003B (zh) 新型二氢嘧啶类化合物、中间体或盐及其制备方法和用途
JP2007532526A (ja) ピラゾロ［４，３−ｄ］ピリミジン類
CN114671876B (zh) 新型茶碱类化合物、异构体或盐及其制备方法和用途
CN114656473B (zh) 吡咯并嘧啶类化合物、异构体或盐及其制备方法和用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120815

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121114

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121121

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130227